|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61P 19/08 | |
| A61K 38/18 | |||
| A61K 38/17 | |||
| A61P 21/00 | |||
| A61P 19/10 | |||
| A61K 31/663 | |||
| C07K 14/705 |
| (11) | Patento numeris | 2475427 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10816109.2 |
| Europos patento paraiškos padavimo data | 2010-09-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-07-18 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-11-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2010/048322 |
| Data | 2010-09-09 |
| (87) | Numeris | WO 2011/031901 |
| Data | 2011-03-17 |
| (30) | Numeris | Data | Šalis |
| 276287 P | 2009-09-09 | US |
| (72) |
SEEHRA, Jasbir, US
KNOPF, John, US
ATTIE, Ken, US
|
| (73) |
Acceleron Pharma, Inc.,
128 Sidney Street, Cambridge, MA 02139,
US
|
| (54) | ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF |
| ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF |